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Abstract 
Radical innovations are of key importance from an economic point of view since they 
bear the potential to trigger the emergence of new technological trends and fuel 
economic prosperity while simultaneously causing far-reaching structural change 
processes. In this paper we focus on the transfer channels of radical innovations 
launched by small and medium-sized firms (SMEs). Based on a unique longitudinal 
dataset covering the observation period 1996 - 2016, we identify and trace back radical 
innovations of SMEs in the German Biotech in order to analyze the extent to which SMEs 
themselves or eventually also other organizations in their direct cooperation surrounding 
benefit from radical innovations in terms of subsequent innovation performance. Results 
from panel data count models indicate that direct cooperation partners of “radical 
innovators” generally seem to show higher innovative performance than partners of the 
control group, i.e. not radical innovating “statistical twin” firms. A more differentiated 
picture emerges if one considers the geographical and technological proximity of the 
cooperation partners.  
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radical innovation, biotech, ego-networks, SME, patent applications, innovative 
performance  
 
 
#2003 Bremen Papers on Economics & Innovation 
Who benefits from radical innovations of 
SMEs? – Empirical evidence from the 
German Biotechnology 
 
Mariia Shkolnykova* and Muhamed Kudic** 
 
*Corresponding author. University of Bremen, Faculty of Business Studies 
and Economics, Max-von-Laue-Straße 1, 28359 Bremen,  
e-mail: mariia.shkolnykova@uni-bremen.de 
** University of Siegen.  
 2/40 
 
 
 
#2003 Bremen Papers on Economics & Innovation 
 
Who benefits from radical innovations of SMEs? – Empirical evidence from the German Biotechnology 
JEL Classifications 
O31; O38; D85
 3/40 
 
 
 
#2003 Bremen Papers on Economics & Innovation 
 
Who benefits from radical innovations of SMEs? – Empirical evidence from the German Biotechnology 
1. Introduction 
The ability of firms to create novelty in terms of innovation is considered to be a 
necessary prerequisite for gaining a sustainable competitive advantage and keeping 
pace with competitors. Firms typically follow unique innovation strategies to cope with 
high levels of ambiguity and complexity, particularly prevalent in knowledge intensive 
technological fields such as biotechnology.  
In this paper we turn our attention to innovation activities of small and medium-
sized enterprises (SME1) in the field of biotechnology, mostly occupied with application 
of biotechnology techniques for the production of goods or services and actively involved 
in research and development (R&D). These firms are frequently referred to as dedicated 
biotech firms (DBFs) (OECD, 2005). DBFs have highly specialized business models, 
which is typically reflected in a very unique resource and knowledge endowment and 
their R&D activities are not seldom subjected to high risks. Accordingly, entry and exit 
dynamics as well as the chance of discovering entirely new methods and applications in 
terms of products and services is certainly overrepresented among DBFs. Radical 
innovations are typically discussed only under the light of radical inventor’s performance 
(e.g. Katila, 2000). However, they bear also the potential to affect other actors and even 
change the technological fields in a fundamental way (Dahlin, Behrens, 2005). It is, 
however, anything but clear to what extent radical innovation remain limited to the radical 
innovator itself or influences its closer surrounding by triggering follow-up innovations. 
Accordingly, we are curious to understand who benefits from radical innovations of 
dedicated biotech firms. More precisely, we apply a network perspective and analyze the 
extent to which firm-specific network structures of small and medium-sized dedicated 
biotech firms – based on formal, publicly-funded R&D partnerships – foster the transfer 
of radically new ideas in a knowledge intensive technological field such as biotechnology.  
We compile and employ a longitudinal unbalanced panel dataset encompassing 
the full set of DBFs in Germany between 1996 and 2016. At the very heart of our 
analytical approach we specify firm-specific ego-network2  for each radical innovator and 
check if (and to what extent) spillovers moves through it by testing if ego-network 
partners show significantly higher patenting activities (in terms of patenting counts) 
compared to partners of statistically equivalent benchmarks of radical innovators 
(“statistical twins”) by using a negative-binomial regression model. We employ a 
propensity score matching procedure two identify a set of “statistical twins” for each 
radical innovator and set up two benchmark datasets in order to evaluate the patenting 
                                               
 
1 Here we use the definition of SME, proposed by European Commission: the enterprise is considered an 
SME, if it has less than 250 employees and “annual turnover not exceeding EUR 50 million, and/or an annual 
balance sheet total not exceeding EUR 43 million” (Recommendation 2003/361/EC) 
2 Ego-networks encompass the ego itself and all its directly linked partners. Indirect connections between 
the alters are included while second tire ties are not included (Hite and Hesterly, 2001). 
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performance of the firms in our sample. The combination of these analytical approaches 
allows us to gain a much deeper understanding of how radical innovations may spill over 
in knowledge intensive technological fields.  
The paper is structured as follows: in Section 2 we first summarize the main 
contributions of previous SMEs research in general and describe existing literature on 
radical innovation and knowledge spillovers. In the end of the chapter hypotheses are 
outlined. Section 3 includes overview of data sources used. Next, we provide an 
overview of the development of the biotechnology industry in Germany. In Section 4 we 
outline our research methodology. In Section 5, we provide basic descriptive statistics 
and results from our statistical analyses. Finally, in Section 6 we provide a brief 
discussion of main findings and outline of some fruitful avenues for further research. 
2. Theory background – externalities, networks and 
innovations 
Economists usually draw upon the concept of ‘externalities’ to approach a 
question like the one we raise above. The externality concept goes back the late 19th 
century (Marshall, 1890) and is still one of the fundamental concepts in welfare 
economics and dominates the debate in economic policy on market failures and 
interventions. The basic idea behind the concept is straightforward. In its most basic 
sense, an externality exists (i.) in consumption, when the shape and position of an 
individual’s indifference curve is affected by the consumption of another individual, (ii.) 
in production, when the production function of one firm depends on use of inputs and 
outputs of another firm (Graaf, 1957; Buchanan and Stubblebine, 1962). Over the years 
two rather contradictory concepts emerged. On the one hand, so-called Marshall-Arrow-
Romer (MAR) externalities – originally developed by Marshall (1890), Arrow (1962), and 
Romer (1986) and later formalized and tested by Glaeser et al., (1992) – are based on 
the notion that knowledge is industry-specific and spillovers appear mainly among similar 
and closely co-located firm in the same industry. On the other hand, so-called ‘Jacobs 
externalities’ go back to the idea that spillovers take place between complementary 
rather than similar industries (Jacobs, 1969). Common to both approaches, however, is 
that the transfer channels and mechanisms often remain unspecified.  
Scholars from evolutionary economics contributed to this debate by introducing 
the systemic innovation perspective (Lundvall, 1992) and emphasizing the role of formal 
and informal networks (Freeman, 1991) for intra-industry and inter-industry knowledge 
transfer processes. In general, networks consist of a well-defined set actors and direct 
or indirect connections among them (Wassermann and Faust, 1994). The specification 
of actors and ties determines the type of network we look at. Innovation networks are 
embedded in a broader socio-economic environment and considered to be an integral 
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part of an industry’s innovation system3  (Kudic, 2015). Inter-organizational innovation 
networks incorporate all type of actors actively involved in R&D processes. Formal as 
well as informal connections among them allow for unilateral, bilateral, or multilateral 
exchange of ideas, information knowledge, and expertise. This, in turn, enables the 
actors involved to recombine and generate new knowledge enclosed in novel goods or 
services to meet market demands and customer needs (cf. Kudic, 2015, p. 47). 
To analyze whether the radical innovations of SME’s spill over to its direct 
partners, we focus on egocentric, inter-firm innovation networks composed of formal links 
within the technological field of biotechnology. Ego-networks are composed of one focal 
actor (ego), his direct connected partners (alters) connections among the alters (Ahuja, 
2000; Hite and Hesterly, 2001). In other fields, ‘ego networks’ are also referred to as 
‘alliance network compositions’ (Baum et al., 2000), ‘alliance constellations’ (Das and 
Teng, 2002; Gomes-Casseres, 2003), ‘alliance portfolios’ (George et al., 2001; 
Hoffmann, 2005; Hoffmann, 2007; Lavie, Miller, 2008), or ‘portfolios of interfirm 
agreements’ (Wuyts et al., 2004).  
However, it is important to note that the existence of direct and indirect ties among 
network actors does not necessarily mean that knowledge identification, transfer and 
learning across firm boundaries takes place without any obstacles or frictions. Cohen 
and Levinthal (1990) were among the first to acknowledged this issue by introducing the 
‘absorptive capacity’ concept which draws attention to an actor’s ability to identify, 
assimilate and use externally available knowledge to commercial ends4.  In a similar vein, 
Simonin (1999) provided us with deep insights on the simultaneous effects of knowledge 
ambiguity and its antecedents – i.e. tacitness, asset specificity, prior experience, 
complexity, partner protectiveness, cultural distance, and organizational distance – for 
the success of technological knowledge transfer through inter-firm alliances.  
The preceding considerations clearly indicate that the ‘network approach’ bear 
the potential to complement and specify the wide-spread but rather abstract notion of 
‘knowledge externality’ since it explicitly acknowledges the often ambiguous nature 
knowledge transfer and learning processes through the channels and conduits of 
complex adaptive systems. A closer look at the empirical literature indicates that we are 
certainly not the first to focus on the relatedness between knowledge exchange, ego-
networks and innovation performance. Previous research mainly focused on the extent 
to which ego-network affect the innovative performance of the focal actor itself. For 
instance, Ahuja (2000) focus on the relatedness between three aspects of firm’s ego-
network characteristics – direct ties, indirect ties as well as structural holes – and 
                                               
 
3 Based on the initial ‘national innovation system’ approaches (Lundvall, 1992, Nelson, 1992, Freeman, 
1992), various specifications were developed, including ‘regional innovation systems’ (Braczyk et al., 1998), 
‘sectoral innovation system’ (Malerba, 2002), ‘technological innovation systems’ (Carlsson et al., 2002). 
4 This important insight has been adapted and extended in several ways. For conceptual extensions, see 
for example: Van Den Bosch et al. (1999); Zahra and George (2002); Lane, et al. (2001). 
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subsequent firm level innovation outcomes and raises awareness for the negative 
innovation effects of structural holes at the network level. Baum et al. (2000) 
demonstrates that the early innovative performance of Canadian biotech startups’ – 
measured by patent grant counts and R&D spending growth – is strongly affected by the 
alliance network composition of these firms at founding. Wuyts et al. (2004) explore the 
impact of different types of alliance portfolio characteristics on firms’ incremental and 
radical innovations as well as on firm profitability. To the best of our knowledge, there is 
no prior research on the extent to which radical innovations of a focal actor affect (or 
‘spill-over’) to its directly – and eventually indirectly – connected alters. 
However, which effect does this special type of innovation bring to companies, 
cooperating close with radical innovators, is still unknown. The research of radical 
innovations in this sense is still limited to focal firms, performing it: investigation of the 
effects, that radical innovation may have on firm´s creation (Shane, 2001) or cooperation 
patterns that help firms to reach radical innovation (Tether, 2002). Thus, it is plausible to 
assume that in case of radical innovations, which present exclusive and unique 
knowledge of one particular actor, spillovers may exist. As direct cooperation partners of 
radical innovators do not bear the risks, connected to its development and introduction, 
we expect positive influence on such activity on partners. Thus, our first hypothesis can 
be stated as follows: 
H1: Radical innovation has a positive impact on innovative performance of direct 
project partners of radical innovators. 
However, there are several factors affecting this relationship. One of them is the 
geographical distance. Closely related firms can better observe development trajectories 
of their neighbors (Hohberger, 2014), which is especially important for the case of tacit 
knowledge transmission. This can explain the success facilitation of innovation 
performance, provided by technological parks (Díez-Vial and Fernández-Olmos, 2015) 
and geographic clusters (Gilbert et al., 2008). On the other hand, it can be stated that 
several meetings pro year along with the usage of modern technologies may make 
distance between partners unimportant for transmitting even tacit knowledge (Breschi 
and Lissoni, 2003). However, we argue that the effect of local (intraregional) knowledge 
spillover may be higher for the case of SMEs, who mostly rely on the local contacts 
(Beugelsdijk, 2009), especially on the connections with universities and successful 
peers. Apart from that, some non-local firms may just do not possess necessary 
capabilities in order to understand local knowledge (Boschma, 2005). Thus, we can state 
that: 
H2: Partners, located in the same region with radical innovator, experience a 
higher influence of radical innovation on their innovative performance. 
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Another strand of literature shows, that not only geography matters.  In order to 
learn, the cognitive abilities of firms should be close enough, but not identical (Boschma, 
2005). Biotechnology firms are often reported to engage in collaborations in order to 
develop new products and services (Hohberger, 2014). However, according to the 
literature, they rather prefer looking for collaboration that complements their capabilities 
(e.g. clinical testing, marketing, management, distribution) (Hohberger, 2014). This can 
also be seen in practice: among the subsidized projects biotechnology firms often have 
soft- and hardware developers or service providers as partners. Apart from that, it is often 
reported that biotechnology SMEs rather communicate with pharmaceutical corporations 
than peers (Kahl, 2015). Thus, we can suppose that: 
H3: Non-biotechnology partners of radical innovation experience a higher 
influence of a radical innovation on their innovative performance. 
3. Technological field and data consolidation 
3.1. Technological field and research focus 
 In our paper we are dealing with the case of German biotechnology. The industry 
presents a case of high-tech sector with the high spatial concentration of the firms. Apart 
from that, inventive outcomes in biotechnology are normally documented in form of 
patents (e.g. Aggarwal and Hsu, 2014), which enables calculation of innovative 
performance indicators. 
As already stated in chapter two, the concept of radical innovation and its 
spillovers is especially important for the case of SMEs. Due to a lack of abundant 
resources small entrepreneurial firm typically fail more often than their larger competitors 
which is referred to in the literature as liability of smallness (Aldrich and Auster, 1986). 
German biotechnology was from its origin driven by several policy initiatives (e.g. 
BioRegio Competition or BioProfile), which explicitly promoted emergence of start-ups. 
This numerous firms, however, appeared to be in the hard financial position after the 
drop of funding in the middle 2000s (Häussler, 2007). On the other hand, independent 
start-ups have to bear with all the costs and risks of failure at any stage of product 
development, production and sales alone. It is especially complicated by the long time 
period between development and sales of specific biotechnology products (Zidorn and 
Wagner, 2012). Thus, in order to mitigate lack of capabilities, these firms need access 
to external knowledge of other firms, research institutions and universities. Therefore, 
different forms of alliances are extremely popular in biotechnology. They are analyzed 
by a number of studies (e.g. Gay and Dousset, 2005; Zidorn and Wagner, 2012; Shin et 
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al., 2016), mostly reporting positive influence of being in alliance on different dimensions 
of firm’s performance. 
In addition, described SMEs have to find niche to operate and specify their 
activities towards special solutions (Zidorn and Wagner, 2012). This may bring new 
products and processes, not known to the field in this combination before. The latter, 
according to Schumpeterian notion, can be related to as radical innovation. Thus, we 
can expect that radical innovations will be the driving power of SMEs activities in 
biotechnology and will be seen relatively often. 
3.2. Data sources 
To construct panel dataset several data sources were used complementary, as 
neither of them could provide full data regarding firm characteristics as well as patenting 
and funding data. The use of raw data sources is outlined below.  
To start with, the population of dedicated biotechnology firms needed to be 
generated for the purpose of radical patents´ identification as well as definition of firm 
characteristics, such as size or age. For that purpose, the dataset provided by BIOCOM 
AG, which is a firm, consolidating statistics on life sciences, was used. Datasets for the 
years 1996-2016 were available for our usage. 
Apart from providing industry books, which consist of the general statistical 
indicators of the field, BIOCOM AG also structures overall firms’ population into different 
categories (e.g. research, pharma, IND1, IND2). IND1 category corresponds to 
dedicated biotechnology firms, which have biotechnology as main field of activity. Exactly 
these firms have served as an initial sample to reach our research goals, by constituting 
narrow dataset, used for radical patents identification. Broader dataset, including other 
firm categories, was used for control purposes. 
However, as we are interested in following radical innovations coming from SMEs, 
the information about firm status and ownership structure was an important component 
needed for the dataset. Thus, in order to follow the firm history chronologically, including 
such events as possible mergers, acquisitions or insolvency procedures, other data 
sources are needed. Apart from that, several entries regarding the size of particular firms 
were not available in BIOCOM AG data. Therefore, several additional sources were used 
complementary to fill this gaps. 
First, Amadeus database from Bureau van Dijk5  was used to additionally checked 
whether firm can be considered SME in particular year with the help of ownership 
                                               
 
5 Accessed in January 2019. 
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structure of a firm. This information was additionally checked in Wiso-Net database6, 
including firm data from register portal. Amadeus database also includes data on 
employees´ number for each firm over the last ten years, which helped to close some 
white spaces.  
To get more information about the history of each firm as well as to learn, which 
of them were founded as university spin-offs, we have additionally manually screened 
firm websites. This information was further used as a control variable and acted as one 
of the predictors of innovative activity. 
As the dependent variable presents the number of patent applications, a decent 
measure reflecting this innovative output had to be chosen. We have used PATSTAT 
Database (Autumn edition 2016) in order to filter patents coming from dedicated 
biotechnology SMEs, which were applied for between 1996 and 2016 for the first time. 
As this version of the database provides the full patent coverage only until 2014, the later 
version of PATSTAT (Spring edition 2019) was used to add patents for the last two years. 
PATSTAT Database, created by European Patent Office (EPO), includes patents applied 
by firms worldwide. Apart from being reliable source of patent data, PATSTAT combines 
data on application itself with data on applicants and inventors, related to patent, as well 
as technological classes (IPC and CPC) assigned to it and number of citations that patent 
received, in a convenient way.  
In order to construct cooperation networks of radical partners, Funding database 
(Förderkatalog) of Federal Ministry of Education and Research was used. Alternative 
way of cooperation measurement, number of co-applied or co-invented patents, was 
additionally checked. However, common subsidized projects have appeared to be a 
better measure of cooperative activity for several reasons:  1) Because of historical 
circumstances, underlined in 2, funding projects was one of the driving forces of 
biotechnology, being thus a common practice in the field; 2) Projects include date of 
cooperation begin, which is for the case of patent application not so clear, as cooperative 
patents may appear several years or several months after start of the cooperation; 3) 
Funding projects present external source of data, whereas patents were included in 
model as a dependent variable. Thus, we exclude selectivity in this case by including in 
the model only those firms, which have patents; 4) Cooperation may not always be 
expressed in terms of patent, especially when it comes to project partners, working in 
different sectors of biotechnology. Overarching projects may be better source of 
knowledge for that case. Funding database could also be used in order to identify 
whether cooperation with universities have taken place for a particular firm. 
                                               
 
6 Accessed in December 2018. 
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3.3. Sample specification 
We first identify all actively operating small and medium sized dedicated biotech 
firms (DBF) in Germany between 1996 and 2016. This time period of 20 years involves 
all stages of industry cycle: emergence of the field, founding of many entrepreneurial 
ventures and industry rapid development in the end of 90s and beginning of 2000s, 
followed by falling of patent activities and numerous exits, starting in the middle of 2000s, 
as well as appearance of new fields, originating from biotechnology, and technological 
change in the end of 2000s and beginning of 2010s. After combining yearly firm datasets 
and identifying firms, that appear in the dataset several times under different names, 
1583 dedicated biotechnology firms, that were actively operating in this time period, were 
left7. 
Majority of identified firms can be related to as SMEs. BIOCOM AG reports, that 
around 85-90% of all dedicated biotechnology enterprises have less than 250 employees 
(e.g. Mietzsch, 2006; Mietzsch, 2016). After accounting for those firms, who were already 
founded as subsidiaries, about 1200 of firms were left (see figure 1)8. 
 
Figure 1. Structure of biotechnology field in Germany 
Out of these firms around a half could be found in PATSTAT, which meant that 
they were seen as an applicant or inventor on at least one patent during the period.  
Patents for sample were filtered basing on the level of patent families in order to ensure 
that no double count is present. Thus, patents included should have their earliest filing 
year between 1996 and 2016. As the result, 4521 family ids or 4937 unique applications 
were defined. These patents further served for the radical entities´ identification. 
                                               
 
7 Help in creation of firm dataset for project purposes was provided by Leonard Prochaska, University of 
Greifswald. 
8 These firms were independent at founding, which does not mean that they were not acquired at some point 
of time. This factor was then taken into account after patent identification. 
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However, in order to perform this issue, control (baseline) group of patents need to 
be created. For it, the sample of 2200 dedicated biotechnology firms (both SMEs and 
large ones), pharmaceutical firms and research institutions9 was combined from 
BIOCOM AG data. After checking for patents, 17280 unique applications could be 
identified10.  
 
 
Figure 2. Patents from SME vs. baseline sample 
Figure 2 shows that trend of SMEs patents corresponds to general patent statistics 
in the field. Most of the patents for both samples are related to the period 2000-2003, 
which is a couple of years after most of the firms were founded. The rapid decline in 
patents can be explained by tendencies in the field, stated above (e.g. according to Kahl 
(2015) re-profiling of many of SMEs) and also negative attention, which genetic research 
has received. 
4. Methodology 
4.1. Research design 
In order to test hypotheses, we combine four analytical approaches (cf. figure 3). 
The first step is to identify radical patents based on technology class information. As can 
be seen, steps two and three can be implemented in any order. Finally, the outcomes of 
the initial analytical steps are included in our estimation model which allows us to 
                                               
 
9 For Research institutions years 2005-2006; 2009; 2011; 2013-2016 are missing, however, the population 
appears to be stable. 
10 Here no filter on application year was needed. 
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distinguish between radical innovators and non-radical “twins” and elaborate on 
innovation outcomes of their direct partners measured by patent counts.  
 
 
 
 
 
 
 
Figure 3. Research design 
1. Identification of patents, presenting radical innovation as well as SMEs, 
that applied for these patents. At this step the definition of radical patent 
was elaborated, based on existing literature. Besides, several filters were 
applied, in order to ensure that only SMEs are included in the radical 
innovators´ sample. 
2. Creation of ego-networks of radical innovators. Here only those radical 
innovators, having funded projects, were taken into account. Their ego-
networks, including all project partners, were constructed. 
3. Identification of “statistical twins” of radical innovators and their ego-
networks. Partners of these firms served as the control group for further 
econometric analysis. 
4. Econometric estimation approach. At the final step hypotheses were 
tested with the help of different specifications of negative binomial 
regression model. Apart from that several robustness checks including 
the usage of the lagged patent variable, were introduced. 
4.2. Identification of radical patents and radical innovators 
As indicated in above, our analysis starts from the identification of radical innovations. 
There exists strand of literature, dealing with identification such kind of innovations. 
However, there still exists no unified definition of what characteristics should a patent 
possess in order to be considered radical. Thus, we apply procedure, composed and 
refined, based on the literature. Firstly, we take method, originally applied by Fleming 
(2001; 2007) in the studies about collaborative creativity and further replicated by several 
other studies for patent data (e.g. Verhoeven et al., 2016; Dahlin and Behrens, 2005; 
Arts et al., 2012, Grashof et al., 2019; Arant et al., 2019). It is based on Schumpeterian 
definition of innovation as a recombinatorial process of existing knowledge (Weitzmann, 
1998) and is characterized as the novel dyad of IPC classes, which did not appear in 
industry before. Verhoeven et al. (2016) relate to this term as “Novelty in Recombination”.  
Econometric estimation 
Identification 
of “statistical twins” 
Identification of radical patents 
Creation of 
ego-networks 
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However important the recombination of classes may be for a patent to be radical, 
the usage of composite indicators is empirically proven to be more reliable in this case. 
Thus, we also relate to the other important characteristic of radical innovation – impact 
that it has on the future of the field. This can be measured using forward citations 
indicator (e.g. Dahlin and Behrens, 2005). Going further, we suggested, that in some 
cases application of important knowledge, created by a radical patent, may take some 
time, therefore, second-order forward citations should also be looked at. 
Apart from that, backward citations can be looked at in order to identify the novelty 
of the patent. Verhoeven et al. (2016) relate to these patent characteristics as to “Novelty 
in Technological Origins” and “Novelty in Scientific Origins”. Analogously to “Novelty in 
Recombination”, this indicator is based on the new dyad of IPC classes, however, focal 
patents´ technology classes here are connected to classes of their backward citations. 
Latter indicator is computed as connection between IPC-code and Non-Patent 
Reference (scientific field) that has not occurred before.  
The difference between first and third indicator lies in the different understanding of 
“new combination”: whereas in the first case patent itself presents a new combination of 
previously unrelated technological categories, in the second case patent uses existing 
knowledge in a novel way. We mostly refer to the first case, therefore, last indicator is 
not investigated thoroughly. 
Applying methodology described above, we needed to identify all possible dyads of 
IPC subclasses11, belonging to the patents of both SMEs´ and baseline sample. Thus, in 
total there occurred to be 31727 of such combinations for SMEs and 111272 for baseline 
sample12. Next, SMEs dyads were juxtaposed to baseline dyads. The patent was 
suspected to be radical if it: 1) was not found within control sample OR 2) appeared in 
control sample later than or in the same year as in SME sample OR 3) appeared in 
control sample 1 year earlier than in SME sample. The latter condition was introduced 
because of 18 months between patent application and publication as well as because 
we are not genuinely interested in radical patents themselves, but rather in firms, that 
possess disruptive potential.   
As the result of this comparison, 396 of potentially radical dyads could be identified, 
belonging to 286 patents. Looking at the timeline of these innovations one can see, that 
most of them relate to 1998 or 1999, which is in line with general peak in biotechnology 
patents. Most favorite patent classes were related to red biotechnology (Preparation ... 
                                               
 
11 We are performing comparison on the level of four digits, e.g. A01H.  
12 Number of patents x number of IPC codes combinations. 
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for medical purposes; …therapeutic activity of chemical compounds/medical 
preparations) or generally to enzymes and peptides research13. 
  
Figure 4. Radical combinations of IPC classes per year 
Then, we checked forward citations of patents, identified before. In order to 
guarantee, that patent received citations (at least initial ones), we only included patents, 
first applied before or in 2012). All 286 patent applications satisfied this condition, 
however, only 108 of them appear to have forward citations. Cutting value here was set 
at 3 citations, which corresponds to about upper 30%. Number of citations of forward 
citations mostly corresponds to forward citations statistics. Here two cases can be 
especially noted: „Kopplung von Proteinen an ein modifiziertes Polysaccharid” (English: 
"Coupling proteins to a modified polysaccharide") – four 1st order citations and 83 2nd 
order citations; „Verfahren zur Gewinnung von Proteinen aus Pflanzen in reiner Form” 
(English: "Process for extracting proteins from plants in their pure form") – eight 1st order 
citations, 153 2nd order citations.  
As the result, 77 patents were left, which belong to 43 firms. These firms were 
additionally checked in order to secure that only SMEs are left in the sample. The reason 
for it are often acquisitions in area of biotechnology: thus, even if the firm was initially 
founded as an entrepreneurial SME, one has to check whether it still had this 
characteristic at the time, when patent was applied for. As the result, 29 firms were left, 
which constituted our end sample. 
                                               
 
13 IPC codes of radical candidates and names of specific subclasses from figure 4 can be found in Appendix 
A. 
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4.3. Creation of ego-networks of radical innovators 
On the first step we could identify radical innovators. However, we are not interested 
in the radical performance of these authors, but rather in that of their project partners. 
Thus, the best methodological way to visualize these partners is via building ego-
networks around radical firms. As we are not interested in the innovative performance of 
exactly these actors, but their project partners, ego-networks of radical innovators 
needed to be constructed Here focal actor, in our case radical innovator, is seen as “ego”. 
Ego is connected to its alters, in our case project partners of radical innovators, via ties. 
Network also includes ties between partners, but does not look at their ties beyond that 
(e.g. Borgatti et al., 2018).  
Thus, at the next step we screened funding database of German Federal Ministry of 
Education and Research (Förderkatalog) in search of project partners. It appeared that 
only 13 firms had projects, involving more than one actor. By connecting obtained firms, 
ego-networks were built (see figure 514). As can be seen, the network shows two big 
components of relatively big project networks. Connectivity there is mostly granted 
through universities or big corporations. Both of these categories, however, are not of 
our primary interest, as it is hard to disentangle influence of radical innovation from other 
factors influencing their innovative performance. For other small firms in biotechnology, 
however, knowledge, created by radical innovation, may be crucial.  
Figure 5. Ego-networks of radical SMEs 
                                               
 
14 List of the nodes can be found in Appendix B. Universities are presented at the level of working groups. If 
network is built on the level of university, much higher connectivity is seen. Universities thus are serving as 
bridges between SMEs. However, in the scope of this paper we are not primarily interested in university-
SME cooperation, therefore no detailed analysis of this issue is provided. 
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Thus, from the scope of project partners, only small, medium and large firms, being 
however single location, were taken into account. After filtering other actors out, 35 
actors were left. Starting from the year of collaboration, number of applied patent families 
pro firm was checked for each firm, using PATSTAT (Autumn 2017 edition)15. Number 
of patents is further used as the dependent variable for count model. 
4.4. Identification of “twin” firms 
Thus, we already identified radical innovators, as well as their partners, which are 
further used for econometric estimation. However, to calculate the effect of radical 
innovation, control sample of firms, who are partners of non-radical dedicated 
biotechnology SMEs, needs to be established. This is done with the help of propensity 
score matching – technique that matches each individual from the sample of radical 
innovators to one or more statistical twins, based on particular characteristics, which both 
firms possess. In the case of these characteristics, also known as baseline covariates, 
they must have two following properties: 1) be independent from each other; 2) have an 
influence on outcome and differ between conditions at baseline (Tanner-Smith and 
Lipsey, 2014).   
It is important to note, that this method is usually used for sociology studies or to test 
the effect of a particular treatment. In these cases, baseline covariates reflect the state 
of subjects to be divided into the groups before the treatment.  For the case of statistical 
twins of radical innovators´ it may become complicated for two reasons: First, different 
firms applied for radical innovations in different time periods and its preparation could 
have taken a firm several years. Second the knowledge, which was produced by radical 
innovation most probably appears before the patent is applied for and stays with the firm 
over time, thus, firm stays “radical” by its nature even after that, so, it is hard for these 
case to take before/after snapshot. Therefore, we identify the firms, which, having the 
same characteristics, appear to be not radical. Thus, we tried to stick to characteristics 
which are relatively stable over time or applied characteristics at current period of time, 
which are: 
• Number of employees that firm has; 
• Size of the network, measured by the number of unique project partners; 
• Whether the firm was founded as spin-off (1) or not (0); 
• Whether the firm has universities in the network (1) or not (0); 
• Whether firm is situated in technology center (1) or not (0) 
                                               
 
15 With adding PATSTAT 2019 Spring edition for 2016 patents. 
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Latter variable can be explained by the fact, that technological centers can promote 
communication among firms, create creative performance and propose technical 
equipment, which are all necessary factors for radical innovation creation. 
For each of the radical firms five “twins” were identified from SME sample (excluding 
radical firms and their partners), from which the most suitable one was manually chosen, 
basing on characteristics provided above. Apart from that, to ensure that the result, 
obtained using radical and selected sample, has not occurred by chance, one more “twin” 
is chosen manually as the second best candidate and one “twin” is chosen using random 
numbers generator. Two additional samples are used to perform robustness checks16.   
4.5. Econometric approach 
Our hypotheses target innovative performance of the partners of both radical 
innovators as well as partners of their statistical “twin” firms. In that case patents serve 
as a well-accepted proxy for measuring innovative performance, especially for such 
industries as biotechnology or pharmaceuticals, where patent applications are important 
and wide-spread form of invention protection and appropriation (e.g. Aggarwal and Hsu, 
2014, Hohberger, 2014). Thus, dependent variable, further used in the model, is the 
number of patents, applied by a firm each year after cooperation with radical innovator 
started. As radical patents usually come close after the founding of the firm and it is 
usually the result of long invention process, no projects had to be excluded from the 
sample. 
When using patent counts as dependent variable, one has to think whether lags are 
reasonable to take into account. It can be explained that patent preparation length is 
from one individual case to another may be different. On the other hand, taking into 
account the field dynamics and the fact, that cooperation could have started earlier than 
a funded project, therefore the patents starting from t year of cooperation are the correct 
measure. Patent lags of one and two years are presented within paper as robustness 
checks. 
In order to account for three hypotheses, three independent variables, related to each 
of them, were built. Thus, to check whether the partnership with radical innovators is 
beneficial, we introduce variable RADICAL, which takes value one whenever the firm 
was the partner of radical innovator and zero if the firm is the partner of its twin. The 
variable is constant for a particular firm across years. If same firm appears in both radical 
and non-radical ego-networks, it was deleted from the panel.  
                                               
 
16 List of twins and all matches can be found in Appendix C. 
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In order to test second hypothesis, the variable REGION was included. It was equal 
to one for interregional and zero for intraregional partners on the NUTS2 level17. For the 
third hypothesis testing another binary variable BIOTECH, taking the value of one for 
dedicated biotechnology firms and zero otherwise. This variable was based on the 
presence of the firm in BIOCOM yearbooks. Both variables according to stated 
hypotheses relate only to the partners of radical innovators. 
Apart from these independent variables several controls were introduced in the 
model. First, variables of age (AGE) and size (EMPL) of the firm were presented. 
Variable AGE presents number of years between firm´s founding and year of 
observation, whereas EMPL corresponds to the number of employees, reported by the 
firm in the observation year. Both variables vary for a firm across panel. Variable SUBS 
estimates whether the firm was a subsidiary or an independent entity in a year of 
observation, whereas SPINOFF reflects whether the firm was founded as a university or 
industry spin-off. Variable UNI identifies whereas a firm had a cooperation with the 
university in form of joint project. This variable takes value of 1 since the start of the 
cooperation with the university and zero if no cooperation tool place.  
Table 1 presents short description of all variables with sources of data, used for their 
collection. 
Table 1. Control variables 
Variable Description Data source 
PATENT Number of patent applications of a firm per 
year 
PATSTAT 2017b 
RADICAL Firm being partner of radical innovator (1) 
or non-radical twin 
Identification procedure, 
explained in 4.2, Förderkatalog 
REGION Partner located in the same NUTS2 region 
with focal firm (1) or in different region (0) 
BICOM AG, Amadeus, WISO-
Net 
BIOTECH Dedicated biotechnology firm (1) or not (0) BICOM AG, Amadeus 
AGE Years between founding of the firm and 
year of observation 
BIOCOM AG, Amadeus 
EMPL Number of employees in a particular year BICOM AG, Amadeus, WISO-
Net 
UNI Firm having university as a partner in 
funded project in the year of observation or 
before (1) or not (0) 
Förderkatalog 
SUBS Firm being subsidiary in the observation 
year (1) or not (0) 
Amadeus 
SPINOFF Firm being spin-off at founding (1) or not 
(0). Variable is constant for one firm across 
all observation periods 
Amadeus, Firms´ websites 
 
Dependent variable (number of patents per year) has a count character and is 
represented by the equation below. Patents per firm do not normally have a normal 
                                               
 
17 The introduction of the variable on NUTS3 level was checked and did not significantly changed results. 
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distribution, being right skewed. Therefore, count model for this case should be preferred 
to linear model specification (e.g. Cincera, 1997). Thus, we limit ourselves to this list of 
models. Furthermore, our data shows overdispersion, confirmed by likelihood-ratio test 
of alpha. In this case negative binomial regression is usually used instead of the Poisson 
specification (e.g. Petruzzelli et al., 2015), and was also applied in this paper. Thus, our 
model generally takes following form (Petruzzelli et al., 2015, Beaujean, Morgan, 2016, 
Cincera, 1997): 
𝜆𝑖?̂? = exp(∑𝛽𝑘𝑋𝑖𝑡 + 𝜀𝑖
𝑘
) 
where X refers to independent and control variables. 
Our data shows panel structure, as we are dealing with patent applications per firm 
per year. This allows accounting for different firm-specific characteristics, firm 
heterogeneity as well as helps to avoid the problem of multicollinearity (Kennedy, 2003). 
Additionally, likelihood-ratio test vs. pooled model favors the usage of panel structure. 
Thus, it will be used in the paper predominantly18. 
5. Results 
5.1. Basic descriptive statistics 
On the next step, having the research question in mind, we construct an unbalanced 
panel dataset, including partners of radical innovators and partners of its radical “twins”19. 
For each firm observations start with the year of the cooperative project start and finish 
2016 or the year when the firm was dissolved, the latter was taken from Amadeus or 
Handelsregister entries, accessed via WISO-net database. In total, 532 entries from 56 
(35 partners of radical firm and 21 partners of non-radical ones) firms were included. 
                                               
 
18 However, by looking at patent data from the firms, several cases are possible here. First, there may be 
firms, who are constantly (or periodically) apply for patents. For such firms count is positive. Second, there 
may be firms, that are not engaged in patenting at all. The reason for that may lie in different operations 
scope or different way of property rights protection. For these firms count is equal to zero. Third, there may 
exist firms in the sample, that are generally involved in patenting activities, however, during the observation 
period no patent application was filed. In that case, although despite being positive over the total period of 
firm´s functioning, count for the period of interest is equal to zero. As presented situation may favor usage 
of zero-inflated models, such specification is presented for all panel samples in Appendix D.  
19 Here the results of analysis with the first manually chosen “twins” sample are presented.   
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When talking about REGION and BIOTECH variables, out of 35 firms 21 can be related 
to as dedicated biotech ones and 20 appear to share the region with their radical firms)20.  
Patenting activities of partners of both radical and non-radical firms are presented in 
table 2. As can be seen, many of the firms, especially those of non-radical “twins” do not 
possess any patent. Apart from that, half of the patenting firms more than half have 1-10 
patents. Additionally, from firms having applications, radical partners show much higher 
diversity of patenting. The most patents (107) are applied for by Vectura GmbH, small 
firm, which is however a subsidiary of international corporation Vectura Group. This trend 
is observed also for other subsidiaries.   
Table 2. Patenting activities, partners of radical and non-radical firms 
Variable Obs Mean Std. 
Dev. 
Min Mdn Max 
Patents, non-radical 
partners 
21 1.90 2.93 0 0 10 
Patents, radical 
partners 
35 8.57 22.48 0 3 107 
  
In the case of control variables, the entries were taken for according years for the case 
of negative binomial regression for panel data and were taken as averages for the case 
of zero-inflated negative binomial regression. Main descriptive statistics for these 
variables across both radical and non-radical firms´ partners are provided in the table 
below. 
  Table 3. Descriptive statistics  
Non-radical partner       
Variable Obs Mean Std. Dev. Min Mdn Max 
AGE 244 13.93 7.98 0 11 166 
EMPL 244 13.06 11.37 1 9 55 
UNI 244 0.96 0.20 0 1 1 
SUBS 244 0.18 0.39 0 0 1 
SPINOFF 244 0.30 0.46 0 0 1 
Radical partner       
Variable Obs Mean Std. Dev. Min Mdn Max 
AGE 288 10.56 8.23 0 8 39 
EMPL 288 38.51 60.12 2 20 329 
UNI 288 0.90 0.31 0 1 1 
SUBS 288 0.34 0.48 0 0 1 
SPINOFF 288 0.27 0.44 0 0 1 
                                               
 
20 Additionally, two of the firms have moved in different region, which changed the value of REGION variable 
for corresponding year. 
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By looking at these measures, several conclusions can be made. First, partners of 
radical innovators are on average much younger than that of non-radical ones. Even not 
accounting for outliers, one can state 3-year difference based on the median value. It 
points at radical innovators´ seeking partnership with younger and probably more 
ambitious firms. Apart from that, partners of radical innovators are generally bigger and 
more independent (not subsidiaries) than that of non-radical partners. However, non-
radical partners are more often founded as spin-offs and have joint projects with 
universities and research institutions. Variables show low to medium level of pairwise 
correlations (see table 4). 
Table 4. Correlation coefficients 
  RADICAL AGE EMPL UNI SUBS SPINOFF 
RADICAL 1.000      
AGE -0.203 1.000     
EMPL 0.272 0.387 1.000    
UNI -0.119 0.125 -0.182 1.000   
SUBS 0.184 -0.107 0.245 0.012 1.000  
SPINOFF -0.035 -0.176 -0.067 -0.217 -0.078 1.000 
5.2. Results of panel regression analysis 
Results of analysis21 are provided in table 6. First, results of the baseline negative 
binomial regression for an unbalanced panel are analyzed. As can be seen, the 
coefficients remain stable for almost all variables, however, the significance of 
coefficients generally decreases when lags are used. The main variable of interest, 
RADICAL, shows positive significant coefficient, meaning that for our sample partners of 
radical innovators show higher innovative performance than that of partners of their 
twins. This result goes in line with our hypothesis, showing presence of positive 
externalities. Apart from that, across all models variables AGE and EMPL show 
significant negative and positive results correspondingly. Therefore, younger and bigger 
partner have higher innovative performance. This may show the presence of certain 
inertia, which does not allow firm continue patenting. Apart from that, constant patenting 
requires substantial financial resources, which micro firms may not possess. In this 
respect, however, it is important to mention that the variable SUBS shows slightly 
significant negative coefficient, meaning that stand-alone SMEs generally tend to patent 
more than subsidiaries. This may be in line with the idea of Kahl (2015), that SMEs in 
                                               
 
21 With first self-matched sample. Other samples as well as different model specifications are presented in 
Appendix D as robustness checks. 
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biotechnology often preform services for big corporations (in this case - parent 
companies), which does not call for own patenting. 
Next, we move to testing hypotheses two and three. For that only partners of radical 
innovators were taken into account, composing 288 observations. As the result of 
negative binomial regression, including only NUTS2 regional coincidence variable, one 
can see negative significant coefficient of REGION variable. This means, that 
interregional partners profit from cooperation with radical partner more, than intraregional 
ones. This contradicts our hypothesis, however, goes in line with some literature, in 
particular note of Breschi and Lissoni (2003), that nowadays even tacit knowledge can 
be translated over distance. Apart from that, competition with other SMEs from the region 
may be tough enough.  
Latter may also serve as an explanation of the result of the model, dealing with 
cognitive similarity between radical innovator and its partner. The variable BIOTECH has 
a negative significant, showing that biotech firms experience lower influence of 
cooperation with radical innovator on their innovative performance. This result goes in 
line with our hypothesis. Thus, radical innovators rather prefer sharing their experience 
with firms, which complement their capabilities rather than with ones, which may 
substitute them.  
By looking at the model with both geographical and cognitive dimension, one can see 
stability of the direction of coefficients, however, distance dimension loses its 
significance. Apart from that, significant results for AGE and EMPL variables are 
confirmed across all models. For the last model UNI variable also shows slightly positive 
coefficient, meaning that firms, cooperating with universities, have higher number of 
patent applications than non-cooperating ones. 
In sum, we find support for hypotheses one and three and could not confirm 
hypothesis two. Generally, partners of radical innovators are more innovative than 
partners of their non-radical twins. Radical innovators tend to exchange knowledge with 
partners across regions and industries. 
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Table 5. Results of regression analysis 
  Baseline model Intra vs. interregional partners Biotech vs. non-biotech partners Intra vs. interregional and biotech vs. 
non-biotech partners 
0 year patent 
lag 
1 year 
patent lag 
2 years 
patent lag 
0 year 
patent lag 
1 year 
patent lag 
2 years 
patent lag 
0 year 
patent lag 
1 year patent 
lag 
2 years patent 
lag 
0 year patent 
lag 
1 year patent 
lag 
2 years 
patent lag 
RADICAL 1.045** 
 (0.430) 
0.855** 
(0.395) 
0.593 
(0.384) 
- - - - - - - - - 
AGE -0.089*** 
(0.024) 
-0.068*** 
(0.021) 
-0.049** 
(0.020) 
-0.129*** 
(0.034) 
-0.097*** 
(0.030) 
-0.079*** 
(0.282) 
-
0.162*** 
(0.0364) 
-0.098*** 
(0.033) 
-0.075** 
(0.030) 
-0.164*** 
(0.036) 
-0.107*** 
(0.032) 
-0.085*** 
(0.029) 
EMPL 0.012** 
(0.005) 
0.016*** 
(0.005) 
0.018*** 
(0.005) 
0.010** 
(0.005) 
0.139*** 
(0.005) 
0.014*** 
(0.005) 
0.010* 
(0.005) 
0.012** 
 (0.006) 
0.013** 
(0.005) 
0.009* 
(0.005) 
0.013** 
 (0.006) 
0.014*** 
(0.005) 
UNI 0.651 
(0.571) 
0.860 
(0.548) 
1.610** 
(0.683) 
0.806 
(0.571) 
0.962* 
(0.556) 
1.800** 
(0.712) 
0.994* 
(0.553) 
0.916 
(0.560) 
1.729** 
(0.705) 
1.015* 
 (0.550) 
1.002* 
(0.557) 
1.816** 
(0.711) 
SUBS -0.703* 
(0.362) 
-0.401 
(0.325) 
-0.174 
(0.315) 
-0.399 
(0.394) 
-0.106 
(0.350) 
0.172 
(0.340) 
-0.273 
(0.361) 
-0.017 
(0.344) 
0.264 
(0.343) 
-0.215 
(0.364) 
-0.010 
(0.352) 
0.232 
(0.349) 
SPINOFF -0.305 
 (0.429) 
-0.222 
(0.405) 
0.173 
(0.391) 
0.336 
(0.631) 
0.294 
(0.557) 
0.349 
(0.514) 
0.437 
(0.710) 
0.239 
(0.596) 
0.175 
(0.514) 
0.662 
(0.722) 
0.387 
(0.604) 
0.350 
(0.530) 
REGION -  - - -1.680** 
(0.672) 
-1.247** 
(0.577) 
-1.045** 
(0.515) 
- - - -0.924 
(0.665) 
-0.888 
(0.635) 
-0.855 
(0.577) 
BIOTECH -  - - - - - -
2.519*** 
(0.901) 
-1.389* 
(0.755) 
-0.941 
(0.618) 
-1.975** 
(0.997) 
-0.814 
(0.833) 
-0.430 
(0.684) 
CONSTANT -0.672 
 (0.760) 
-1.272* 
(0.691) 
-2.228*** 
(0.792) 
1.544* 
(0.891) 
0.407 
(0.790) 
-1.086 
(0.882) 
2.410** 
(1.012) 
0.731 
(0.948) 
-0.984 
(0.977) 
2.610** 
(1.016) 
0.826 
(0.911) 
-0.854 
(0.953) 
Log likelihood -394.931 -422.021 -436.373 -294.085 -312.022 -319.750 -296.483 -313.579 -320.882 -291.991 -311.496 -319.545 
Observations 532 532 532 288 288 288 288 288 288 288 288 288 
Standard errors in parentheses, ***- significance at 0.01 level, ** - significance at 0.05 level, * - significance at 0.1 level 
Year effects are absent in all of present specifications, because of their insignificance.
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6. Discussion and conclusion 
This paper has an aim to show whether the unique knowledge, created by radical 
innovations spreads out across firm boundaries and may influences cooperation partners 
of radically innovating SMEs in biotech. We have obtained highly robust result over all 
model specification, which shows that SMEs profit from being involved in cooperation 
with a radical innovator. As already stated, there may be several reasons for it. Firstly, 
communication existing between firms, engaged in scientific cooperation, is usually more 
intense than between firms, that do not cooperate. For sure, in case of joint work, 
knowledge and experience is shared, cooperation partners are not seen as competitors. 
Apart from that, a partner SME has a better possibility to observe routines of radical 
innovators and learn, how innovations are done there. Besides, our results show that for 
non-biotech firms as well as for firms across regions positive influence of partnership 
with radical innovator is higher than for the counterparts. It shows, that because of the 
high overlap of the capabilities, which exists among firms from the same industry and 
same region, less opportunities for learning can be found.  From the other hand, firms 
from different regions and complementary industries can profit from engaging in the 
cooperation via extending their knowledge space.  
Our study complements the existing body of literature in several ways. Based on a 
unique longitudinal dataset and a conceived research design we combine different 
analytical instruments to answer a still unexplored research question, i.e. the extent to 
which partners of radical innovations may benefit for their radical innovation activities. 
Our findings have far-reaching implications for policy makers. The promotion of young 
and highly innovative companies can have positive consequences for other firms and 
organizations within an economy. More precisely, regional funding programs designed 
to stimulate and support radical innovation within SMEs may have a positive effect on 
economic actors in other regions. Often neglected network between radically innovating 
SMEs and their direct partners allow for bridging long geographical distances and thus 
serve as important transmission channels for knowledge spillovers. Even more 
important, radical innovations also spill over to companies from other fields of 
technology. Hence, our findings suggest that technology-centered funding programs 
may exert a much broader impact than previously assumed. At the same time, our study 
allows for deriving some interesting recommendations for managers and decision-
makers in companies. The establishment and maintenance of partnerships to companies 
with radically new ideas can pay off in terms of innovation outcomes. When choosing a 
partner, geographical closeness is often overestimated, especially in the age of digital 
technologies, making it easier than ever to bridge the even far distances. 
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However, there may be some limitations of our study. First, we have focused on ego-
networks of the radical innovators, not taking into account second and third tier partners 
of their partners. Extending the research to full networks may complement our 
understanding of knowledge spillovers via much more complex overall industry or 
technology network. Apart from that, the propensity score matching technique used is a 
very sensitive instrument. Usage of one or two different parameters could have brought 
somehow different results for the twins. Whenever more data is available, the procedure 
can be run one more time and more robustness checks, using different samples of twins, 
may be performed. One dimension that needs to be examined more thoroughly is 
geographic distance between radical innovators and its partners. For the purpose of this 
study we used a very simplistic and coarse geographical measure. Here we see great 
opportunities for future research contributions. 
The successful entrepreneurs of tomorrow are often those who think out of the box 
and deviate from established paths. Our study highlights the outstanding importance of 
ingenious, creative, risk affine individuals and their radically innovative companies for the 
technological prosperity of an economy, an aspect that Joseph Alois Schumpeter 
emphasized over 100 years ago. Cooperation with these players provides an important 
vehicle for other technologically and geographically distant economic actors participating 
in their success. 
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Appendix A. IPC codes of candidates for radical patents 
IPC code Name of the subclass 
C12Q Measuring or testing processes involving enzymes, nucleic acids or microorganisms 
(immunoassay G01N 33/53); compositions or test papers therefor; processes of 
preparing such compositions; condition-responsive control in microbiological or 
enzymological processes 
C12N Microorganisms or enzymes; compositions thereof (biocides, pest repellants or 
attractants, or plant growth regulators containing microorganisms, viruses, microbial 
fungi, enzymes, fermentates, or substances produced by, or extracted from, 
microorganisms or animal material A01N 63/00; medicinal preparations A61K; 
fertilisers C05F); propagating, preserving, or maintaining microorganisms; mutation 
or genetic engineering; culture media (microbiological testing media C12Q 1/00) 
C12M Apparatus for enzymology or microbiology (installations for fermenting manure 
A01C 3/02; preservation of living parts of humans or animals A01N 1/02; brewing 
apparatus C12C; fermentation apparatus for wine C12G; apparatus for preparing 
vinegar C12J 1/10) 
G01N  Investigating or analysing materials by determining their chemical or 
physical properties (measuring or testing processes other than immunoassay, 
involving enzymes or microorganisms C12M, C12Q) 
C40B Combinatorial chemistry; libraries, e.g. chemical libraries, in silico libraries 
C12P  Fermentation or enzyme-using processes to synthesise a desired chemical 
compound or composition or to separate optical isomers from a racemic mixture 
C07K peptides (peptides containing β-lactam rings C07D; cyclic dipeptides not having in 
their molecule any other peptide link than those which form their ring, e.g. 
piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D 519/02; 
single cell proteins, enzymes C12N; genetic engineering processes for obtaining 
peptides C12N 15/00) 
A61K Preparations for medical, dental, or toilet purposes (devices or methods specially 
adapted for bringing pharmaceutical products into particular physical or 
administering forms A61J 3/00; chemical aspects of, or use of materials for 
deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, 
absorbent pads or surgical articles A61L; soap compositions C11D) 
B01J Chemical or physical processes, e.g. catalysis or colloid chemistry; their relevant 
apparatus 
C07H Sugars; derivatives thereof; nucleosides; nucleotides; nucleic acids (derivatives of 
aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C 59/105, 
C07C 59/285; cyanohydrins C07C 255/16; glycals C07D; compounds of unknown 
constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA 
concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation 
or purification C12N 15/00; sugar industry C13) 
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Appendix B. List of nodes of ego-networks, radical firms 
Node Node number Ego? 
3T TextilTechnologieTransfer GmbH 1  
4SC Discovery GmbH - F&E Abt. 2  
ACGT ProGenomics AG - Geschäftsbereich 3 - Therapeutika 3  
Amedrix GmbH 4  
AMSilk GmbH 5 yes 
AptaIT GmbH 6  
Aventis Research & Technologies GmbH & Co. KG - Operative Forschung 7  
Axiogenesis AG 8 yes 
Bayer Technology Services GmbH - BTS-PT-Process Design- Process Analysis 9  
BIOPHARM Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH 10 yes 
Biotechnologie-Gesellschaft Mittelhessen mbH 11 yes 
Braunform GmbH 12  
Cellzome AG 13  
Charité - Universitätsmedizin Berlin - Campus Virchow-Klinikum - Institut für 
Medizinische Genetik 
14  
Charité - Universitätsmedizin Berlin - Labor für Tissue Engineering 15  
Charité - Universitätsmedizin Berlin - Medizinische Klinik mit Schwerpunkt 
Rheumatologie und Klinische Immunologie 
16  
chimera biotec GmbH 17 yes 
chimera biotec GmbH - Biomedizinzentrum Dortmund 18 yes 
Christian-Albrechts-Universität zu Kiel - Agrar- und Ernährungswissenschaftliche 
Fakultät - Institut für Phytopathologie 
19  
Christian-Albrechts-Universität zu Kiel - Agrar- und Ernährungswissenschaftliche 
Fakultät - Institut für Phytopathologie - Abt. Molekulare Phytopathologie 
20  
Christian-Albrechts-Universität zu Kiel - Universitätsklinikum Schleswig-Holstein - 
Campus Kiel - Hautklinik 
21  
co.don Aktiengesellschaft 22  
Coley Pharmaceutical GmbH 23  
conoGenetix biosciences GmbH 24  
Corimmun GmbH 25  
Crelux GmbH - F&E Abteilung 26  
Deutsches Krebsforschungszentrum (DKFZ) - Abt. Translationale Immunologie 
(D015) 
27  
DOT GmbH - Bereich Forschung und Entwicklung 28  
Dr. Lerche KG 29  
Endolab Mechanical Engineering GmbH 30  
Eppendorf Instrumente GmbH 31  
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FEG Textiltechnik Forschungs- und Entwicklungsgesellschaft m.b.H. 32  
FEG Textiltechnik Forschungs- und Entwicklungsgesellschaft m.b.H. - Abt. 
Entwicklung 
33  
Fraunhofer-Institut für Angewandte Informationstechnik (FIT) 34  
Fraunhofer-Institut für Siliziumtechnologie (ISIT) 35  
Freie Universität Berlin - Fachbereich Biologie, Chemie, Pharmazie - Institut für 
Biologie - Angewandte Genetik 
36  
Freie Universität Berlin - Fachbereich Biologie, Chemie, Pharmazie - Institut für 
Chemie und Biochemie 
37  
Friedrich-Schiller-Universität Jena - Physikalisch-Astronomische Fakultät - Institut 
für Materialwissenschaft und Werkstofftechnologie 
38  
GeSIM Gesellschaft für Silizium-Mikrosysteme mbH 39  
Graffinity Pharmaceuticals GmbH 40 yes 
GS Gebhardt & Schäfer Industrie-Elektronik GmbH 41  
Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. - Institut für Mikro- 
und Informationstechnik (IMIT) 
42  
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und 
Umwelt (GmbH) - Institut für Lungenbiologie 
43  
Helmholtz-Zentrum für Infektionsforschung GmbH - Abt. Molekulare 
Biotechnologie 
44  
humediQ GmbH 45  
ibidi GmbH 46  
In Vitro Biotec GmbH 47  
Infineon Technologies AG 48  
Inosim GmbH 49  
Intana Bioscience GmbH 50  
Jenpolymer Materials LTD & Co. KG 51  
Julius-Maximilians-Universität Würzburg - Physiologisch-Chemisches Institut 52  
Kliniken der Stadt Köln gGmbH - Klinik für Anästhesiologie und operative 
Intensivmedizin 
53  
Klinikum der Universität München - Campus Großhadern - Medizinische Klinik und 
Poliklinik I 
54  
Klinikum rechts der Isar der Technischen Universität München - Klinik für 
Orthopädie und Unfallchirurgie 
55  
KTB Tumorforschungsgesellschaft mbH 56  
Lindauer DORNIER Gesellschaft mit beschränkter Haftung - Abt. GS 57  
Ludwig-Maximilians-Universität München - Fakultät für Chemie und Pharmazie - 
Department Pharmazie - Pharmazeutische Technologie und Biopharmazie 
58  
Ludwig-Maximilians-Universität München - Fakultät für Physik 59  
Martin-Luther-Universität Halle-Wittenberg - Fachbereich Ingenieurwissenschaften - 
Institut für Biogineering 
60  
Martin-Luther-Universität Halle-Wittenberg - Naturwissenschaftliche Fakultät I - 
Institut für Biochemie und Biotechnologie 
61  
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Martin-Luther-Universität Halle-Wittenberg - Naturwissenschaftliche Fakultät I - 
Institutes für Biologie - Genetik 
62  
Mathys Orthopädie GmbH 63  
Medizinische Hochschule Hannover - Klinik und Poliklinik für Dermatologie und 
Venerologie 
64  
Medizinische Hochschule Hannover - Orthopädische Klinik (im Annastift) 65  
Medizinische Hochschule Hannover - Zentrum Innere Medizin - Klinik für Nieren- 
und Hochdruckerkrankungen 
66  
Milupa GmbH - Numico Research - Group Germany 67  
Molzym GmbH & Co. KG 68  
MorphoSys AG 69  
MPB Cologne GmbH 70 yes 
NanoTemper Technologies GmbH 71  
nanotype GmbH 72 yes 
NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen 73  
november Aktiengesellschaft Gesellschaft für Molekulare Medizin - 
MD1/Medizinische Diagnostik 
74 yes 
ONCOLEAD GmbH & Co. KG 75  
Orthopädische Universitätsklinik Heidelberg 76  
Planton GmbH 77 yes 
Priaxon AG 78  
Proteome Sciences R&D GmbH & Co. KG 79  
Proteros Biostructures GmbH 80  
QUALIMED Innovative Medizinprodukte Gesellschaft mit beschränkter Haftung 81  
Rheinisch-Westfälische Technische Hochschule Aachen - Fakultät 4 - 
Maschinenwesen - Lehrstuhl und Institut für Allgemeine Mechanik 
82  
Robert Bosch GmbH - Zentralbereich Forschung und Vorausentwicklung - 
Mikrosystemtechnik 
83  
Ruprecht-Karls-Universität Heidelberg - Medizinische Fakultät und 
Universitätsklinikum Mannheim - Neurochirurgische Klinik 
84  
Ruprecht-Karls-Universität Heidelberg - Medizinische Fakultät und 
Universitätsklinikum Mannheim - Orthopädisch-Unfallchirurgisches Zentrum 
85  
Scil Proteins GmbH 86 yes 
Siemens Aktiengesellschaft - Zentralabt. Technik (ZT EN 1) 87  
SIRION BIOTECH GmbH 88  
Südzucker Aktiengesellschaft Mannheim/Ochsenfurt - Zentralabt. Forschung, 
Entwicklung und Services (ZAFES) 
89  
SuppreMol GmbH 90  
SWITCH Biotech AG 91 yes 
Technische Universität Dortmund - Fakultät Chemie - Lehrstuhl für Biologisch-
Chemische Mikrostrukturtechnik 
92  
Technische Universität München - Fakultät für Medizin - Institut für Medizinische 
Mikrobiologie, Immunologie und Hygiene 
93  
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Technische Universität München - Fakultät für Medizin - Institut für Pharmakologie 
und Toxikologie 
94  
Technische Universität München - Wissenschaftszentrum Weihenstephan - 
Forschungsdepartment Biowissenschaftliche Grundlagen - Lehrstuhl für Biologische 
Chemie 
95  
TransTissue Technologies GmbH 96 yes 
Trianta Immunotherapies GmbH 97  
Universität Bayreuth - Fakultät für Angewandte Naturwissenschaften - Lehrstuhl 
Bioprozesstechnik 
98  
Universität Bayreuth - Fakultät für Angewandte Naturwissenschaften - Lehrstuhl für 
Biomaterialien 
99  
Universität Bremen - Fachbereich 02 Biologie/Chemie - Institut für Biochemie - 
Centrum für Biomolekulare Interaktionen in Bremen (CBIB) 
100  
Universität Regensburg - Universitätsklinikum - Klinik und Poliklinik für Innere 
Medizin I 
101  
Universitätsklinikum Jena - AG Experimentelle Rheumatologie 102  
Universitätsklinikum Jena - Medizinische Fakultät - AG Experimentelle 
Rheumatologie - Lehrstuhl für Orthopädie 
103  
Universitätsklinikum Würzburg - Neurologische Klinik und Poliklinik 104  
Vectura GmbH 105  
Wilex AG 106  
Xerion Pharmaceuticals AG 107  
XL-protein GmbH 108  
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Appendix C. List of nodes of ego-networks, radical firms 
Radical firm Manual match 1 Manual match 2 Random match 
1 
Random match 
2 
MPB Cologne 
GmbH 
Kelman 
Gesellschaft für 
Geninformation 
mbH 
LipoNova AG Kelman 
Gesellschaft für 
Geninformation 
mbH 
 
Otogene AG 
Switch Biotech AG Xenomed GmbH 
 
TherapySelect 
GmbH & Co. KG 
 
TherapySelect 
GmbH & Co. KG 
 
Xenomed GmbH 
 
Biotechnologie-
Gesellschaft 
Mittelhessen mbH 
GAMU - 
Gesellschaft für 
angewandte 
Mykologie und 
Umweltstudien 
mbH 
 
m-phasys GmbH  
 
GAMU - 
Gesellschaft für 
angewandte 
Mykologie und 
Umweltstudien 
mbH 
 
EnerGene 
 
Scil Proteins 
GmbH 
DECODON 
GmbH 
 
Cevec 
Pharmaceuticals 
GmbH 
Exosome 
Diagnostics 
GmbH 
 
Ganomycin 
GmbH 
 
AMSilk GmbH Across Barriers 
GmbH 
Exosome 
Diagnostics 
GmbH 
XanTec 
bioanalytics 
GmbH 
DECODON 
GmbH 
 
nanotype GmbH Lionex GmbH 
 
Arthro kinetics 
AG 
BCP AG 
evolutionary 
concepts 
Cavis GmbH 
Chimera Biotec 
GmbH 
ProteoSys AG NascaCell 
Technologies AG 
N-Zyme BioTec 
GmbH 
NascaCell 
Technologies 
AG 
november AG BIOSERV AG 
 
Institut für 
Pflanzenkultur 
Biotype 
Diagnostic 
GmbH 
BIOSERV AG 
 
metanomics 
GmbH 
Tinplant TraitGenetics 
GmbH 
Genotype GmbH Biognosis GmbH 
BIOPHARM 
GmbH 
Autoimmun 
Diagnostika 
GmbH 
Mediagnost 
GmbH 
Senova 
 
Lophius 
Biosciences 
GmbH 
Axiogenesis AG GENterprise 
GmbH 
Bioglobe GmbH JPT Peptide 
Technologies 
GmbH 
GENterprise 
GmbH 
Planton GmbH Bioglobe GmbH GENterprise 
GmbH 
GENterprise 
GmbH 
PSF biotech AG 
TransTissue 
Technologies 
GmbH 
SILANTES 
GmbH 
Capsulution 
Pharma AG 
SILANTES 
GmbH 
Protagen AG 
Random matches were identified with Random Number Service random.org. For that reason, 
some randomly chosen “twin” firms coincide with manually chosen ones. 
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Appendix D. Robustness checks 
Manual check 2 
 Negative binomial regression Zero-inflated negative binomial model 
 0 year 
patent lag 
1 year 
patent lag 
2 years 
patent lag 
0 year 
patent lag 
1 year patent lag 2 years patent lag 
RADICAL 0.364 
 (0.359) 
0.180  
(0.346) 
0.094  
(0.342) 
0.897** 
(0.352) 
0.911*** 
(0.341) 
1.036*** 
(0.347) 
AGE -0.074*** 
(0.023) 
-0.050*** 
(0.018) 
-0.041*** 
(0.015) 
0.179 
(0.032) 
0.014 
(0.032) 
0.008 
(0.030) 
EMPL 0.008** 
(0.004) 
0.010** 
(0.004) 
0.008**  
(0.004) 
-0.001 
(0.005) 
-0.001 
(0.004) 
0.001 
(0.004) 
UNI 0.793 
(0.489) 
0.775* 
(0.447) 
1.120** 
(0.448) 
-0.533 
(0.922) 
-0.656 
(0.886) 
-0.814 
(0.880) 
SUBS -0.403 
 (0.293) 
-0.152 
(0.269) 
0.077  
(0.262) 
0.942*** 
(0.355) 
0.949*** 
(0.343) 
0.845** 
(0.351) 
SPINOFF 0.128 
 (0.365) 
0.138 
(0.355) 
0.256  
(0.351) 
0.318 
(0.377) 
0.292 
(0.366) 
0.283 
(0.370) 
CONSTANT -0.399 
 (0.622) 
-0.599 
(0.554) 
-1.138**  
(0.540) 
1.192  
(0.923) 
1.460*  
(0.882) 
1.687*  
(0.876) 
Log likelihood -488.553 -519.235 -532.756 -147.093 -152.140 -154.232 
Observations 628 628 628 74 74 74 
 
Standard errors in parentheses, ***- significance at 0.01 level, ** - significance at 0.05 level, * - significance 
at 0.1 level 
Zero-inflated negative binomial model was evaluated only with the variable of prior interest because of 
convergence issues 
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Random match 1 
 Negative binomial regression Zero-inflated negative binomial model 
 0 year 
patent lag 
1 year 
patent 
lag 
2 years 
patent lag 
0 year 
patent lag 
1 year patent lag 2 years patent lag 
RADICAL 0.229 
 (0.349) 
0.133  
(0.351) 
0.304 
(0.325) 
1.402*** 
(0.350) 
1.350*** 
(0.351) 
-0.077 
(0.531) 
AGE -0.051*** 
(0.019) 
-0.025** 
(0.017) 
-0.030* 
(0.017) 
- - - 
EMPL 0.006 
(0.004) 
0.008* 
(0.004) 
0.008*  
(0.004) 
- - - 
UNI 0.342 
(0.524) 
0.497 
(0.502) 
1.436** 
(0.663) 
- - - 
SUBS -0.300 
 (0.283) 
-0.089 
(0.264) 
0.095  
(0.258) 
- - - 
SPINOFF 0.201 
 (0.401) 
-0.246 
(0.406) 
0.409  
(0.386) 
- - - 
CONSTANT -0.154 
 (0.638) 
-0.467 
(0.608) 
-1.892**  
(0.753) 
1.079  
(0.238) 
1.224  
(0.237) 
0.316  
(0.345) 
Log likelihood -508.986 -538.593 -542.819 -166.623 -172.891 -88.631 
Observations 649 649 649 53 53 53 
 
Standard errors in parentheses, ***- significance at 0.01 level, ** - significance at 0.05 level, * - significance 
at 0.1 level 
Zero-inflated negative binomial model was evaluated only with the variable of prior interest because of 
convergence issues 
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Random match 2 
 Negative binomial regression Zero-inflated negative 
binomial model 
 0 year patent 
lag 
0 year 
patent lag 
0 year 
patent lag 
0 year 
patent lag 
1 year 
patent lag 
2 years 
patent lag 
RADICAL 0.303 
 (0.376) 
0.178 
(0.356) 
0.134 
(0.335) 
0.050 
(0.414) 
0.136 
(0.402) 
0.192 
(0.403) 
AGE -0.089*** 
(0.022) 
-0.052***  
(0.020) 
-0.038*  
(0.020) 
0.070* 
(0.039) 
0.073* 
(0.038) 
0.068* 
(0.037) 
EMPL 0.011*** 
(0.004) 
0.011**  
(0.005) 
0.010**  
(0.005) 
-0.003 
(0.005) 
-0.003 
(0.005) 
-0.002 
(0.004) 
UNI 0.646 
(0.484) 
0.537  
(0.454) 
0.832*  
(0.473) 
-0.641 
(1.331) 
-0.892 
(1.289) 
-1.088 
(1.252) 
SUBS -0.316 
 (0.309) 
0.012  
(0.279) 
0.238  
(0.274) 
0.809* 
(0.418) 
0.854** 
(0.406) 
0.853** 
(0.411) 
SPINOFF -0.191 
 (0.398) 
-0.136  
(0.383) 
-0.007 
 (0.364) 
0.542 
(0.443) 
0.437 
(0.433) 
0.388 
(0.421) 
CONSTANT -0.113 
 (0.602) 
-0.441  
(0.545) 
-1.136**  
(0.543) 
1.357 
 (1.322) 
1.584  
(1.282) 
1.791  
(1.252) 
Log likelihood -505.249 -530.046 -542.310 -141.796 -141.816 
 
-145.921 
Observations 563 563 563 64 64 64 
 
Standard errors in parentheses, ***- significance at 0.01 level, ** - significance at 0.05 level, * - significance 
at 0.1 level 
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